

RECEIVED

FEB 04 2002

TECH CENTER 1600/2300



Elan20037.ST25.txt
SEQUENCE LISTING

<110> O"Mahony, Daniel J
Seveso, Michela

<120> Antibodies To Peptides That Target GIT Receptors And Related
Methods

<130> E1067/20037

<140> US 09/443,780

<141> 1999-11-19

<150> US 60/109,036

<151> 1998-11-19

<160> 12

<170> PatentIn version 3.1

94 <210> 1

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Random peptide

<220>

<221> MISC_FEATURE

<222> (1)..(1)

<223> Linked to dansyl group

<400> 1

Thr Asn Ala Lys His Ser Ser His Asn Arg Arg Leu Arg Thr Arg
1 5 10 15

<210> 2

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Random peptide

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Linked to dansyl group

<400> 2

Ser Asp Asn Ala Lys Glu Pro Gly Asp Tyr Asn Cys Cys Gly Asn Gly
1 5 10 15

Asn Ser Thr Gly
20

<210> 3
<211> 16
<212> PRT
<213> Artificial Sequence

94
<220>
<223> Random peptide

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Linked to dansyl group

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> D-amino acid

<220>
<221> MISC_FEATURE
<222> (6)..(6)
<223> D-amino acid

<220>
<221> MISC_FEATURE
<222> (10)..(10)
<223> D-amino acid

<220>
 <221> MISC_FEATURE
 <222> (12)..(13)
 <223> D-amino acid

<400> 3

Thr Arg Lys Ser Ser Arg Ser Asn Pro Arg Gly Arg Arg His Pro Gly
 1 5 10 15

<210> 4
 <211> 36
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Random peptide

<400> 4

Ser Asp His Ala Leu Gly Thr Asn Leu Arg Ser Asp Asn Ala Lys Glu
 1 5 10 15

Pro Gly Asp Tyr Asn Cys Cys Gly Asn Gly Asn Ser Thr Gly Arg Lys
 20 25 30

Val Phe Asn Arg
 35

<210> 5
 <211> 29
 <212> PRT
 <213> Artificial sequence

<220>
 <223> Random peptide

<400> 5

Asn Leu Arg Ser Asp Asn Ala Lys Glu Pro Gly Asp Tyr Asn Cys Cys
 1 5 10 15

Gly Asn Gly Asn Ser Thr Gly Arg Lys Val Phe Asn Arg
20 25

<210> 6
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> Random sequence

<400> 6

Ser Asp Asn Ala Lys Glu Pro Gly Asp Tyr Asn Cys Cys Gly Asn Gly
1 5 10 15

Asn Ser Thr Gly
20

<210> 7
<211> 40
<212> PRT
<213> Artificial Sequence

<220>
<223> Random peptide

<400> 7

Ser Thr Pro Pro Ser Arg Glu Ala Tyr Ser Arg Pro Tyr Ser Val Asp
1 5 10 15

Ser Asp Ser Asp Thr Asn Ala Lys His Ser Ser His Asn Arg Arg Leu
20 25 30

Arg Thr Arg Ser Arg Pro Asn Gly
35 40

<210> 8
<211> 15
<212> PRT
<213> Artificial Sequence

<220>

<223> Cyclic (internal) random peptide

<400> 8

Thr Asn Ala Lys His Ser Ser Cys Asn Arg Arg Leu Arg Cys Arg
1 5 10 15

<210> 9

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Cyclic (internal) random peptide

<400> 9

Thr Asn Ala Lys His Ser Ser Cys Asn Arg Arg Cys Arg Thr Arg
1 5 10 15

<210> 10

<211> 41

<212> PRT

<213> Artificial Sequence

<220>

<223> Random peptide

<400> 10

Ser Ala Arg Asp Ser Gly Pro Ala Glu Asp Gly Ser Arg Ala Val Arg
1 5 10 15

Leu Asn Gly Val Glu Asn Ala Asn Thr Arg Lys Ser Ser Arg Ser Asn
20 25 30

Pro Arg Gly Arg Arg His Pro Gly Gly
35 40

<210> 11

<211> 16

<212> PRT
<213> Artificial Sequence

<220>
<223> Random peptide

<220>
<221> MISC_FEATURE
<222> (6)..(6)
<223> D-amino acid

<220>
<221> MISC_FEATURE
<222> (12)..(12)
<223> D-amino acid

<400> 11

Thr Arg Lys Ser Ser Arg Ser Asn Pro Arg Gly Arg Arg His Pro Gly
1 5 10 15

<210> 12
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Random peptide, D form, retroinversion

<220>
<221> MISC_FEATURE
<222> (1)..(16)
<223> D-amino acid

<400> 12

Gly Pro His Arg Arg Gly Arg Pro Asn Ser Arg Ser Ser Lys Arg Thr
1 5 10 15